Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints, causing warm, swollen, and painful joints, but can also involve other parts of the body such as the skin, eyes, lungs, and heart, with symptoms typically worsening after periods of rest. It is more common in women and often starts in middle age, although it can occur at any age, with its exact cause involving a combination of genetic, environmental, and hormonal factors.
Health Outcomes
- Accelerated Immune Response Maturation
- Achieved Inflammation Homeostasis
- Activated Immune Response
- Activation of Nrf2 Pathway
- Additional Therapeutic Benefits
- Adjusted Immune Function
- Altered CD4+ T-cell Cytokine Levels
- Altered Chemokine Response
- Altered Dominant Microbial Community
- Altered Expression of Immune Products
- Altered Expression of Immune-Related Genes
- Altered IFN-γ Levels
- Altered Immune Response
- Altered Microbial Composition
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Serum IL-6 Levels
- Altered Serum Immune Protein Levels
- Altered Systemic Immune Response
- Altered T Cell Migratory Behavior
- Altered T Cell Subsets
- Altered TH1/TH2 Immune Response
- Association with Sarcopenia
- Balanced T-Cell Differentiation
- Balanced Treg/Th17 Regulation
- Beneficial Clinical Effects
- Changes in Inflammatory Markers
- Chronic Immune Activation
- Confirmed Safety of Treatment
- Decreased Naïve CD45RA+ T Helper Cells
- Decreased Peripheral CD3⁺ T Lymphocyte Count
- Decreased Peripheral T Cell Response
- Decreased Prevotella Copri Relative Abundance
- Decreased TNF-α Production in Immune Cells
- Decreased TNFα Levels
- Delayed Disease Progression
- Delayed Onset of Type 1 Diabetes
- Delayed Osteoporosis Progression
- Downregulated Complement System Activity
- Duration of Symptoms
- Elevated BSA Antibody Levels
- Elevated Blood Cytokine Levels
- Elevated IL-10 Levels
- Elevated IL-22 Levels
- Elevated IL-6 Levels
- Elevated IgG1 Levels
- Elevated Interleukin-10 Levels
- Elevated Interleukin-12 Levels
- Elevated Interleukin-17 Levels
- Elevated Interleukin-6 Levels
- Elevated Interleukin-8 Levels
- Elevated Serum IFN-γ Levels
- Elevated Serum IL-2 Levels
- Elevated Serum Immunoglobulin Levels
- Elevated Serum Metabolites in Response to Inflammation
- Elevated Serum Substance P Levels
- Elevated Serum TNF-α Levels
- Elevated Serum Total Ig Levels
- Elevated TNF-α Expression Level
- Elevated Total IgM Levels
- Enhanced Adjuvanticity
- Enhanced Alternative Complement Activity
- Enhanced Anti-Inflammatory Cytokine Production
- Enhanced Anti-Inflammatory Cytokine Secretion
- Enhanced Anti-inflammatory Cytokine Expression During Healing
- Enhanced Anti-inflammatory Cytokine Levels
- Enhanced Anti-inflammatory Properties
- Enhanced Anti-inflammatory Response
- Enhanced Antioxidant Capabilities
- Enhanced Antioxidant Response
- Enhanced B-Cell Proliferation
- Enhanced Cell Viability Under Oxidative Stress
- Enhanced Cell-Mediated Immunity
- Enhanced Complement Pathway Activity
- Enhanced Cytokine Production
- Enhanced Cytokine Response
- Enhanced Delayed-Type Hypersensitivity Response
- Enhanced Dendritic Cell-T Cell Interaction
- Enhanced Host Defense Peptides Activation
- Enhanced IL-12 Production
- Enhanced Immune Function Post-Cessation
- Enhanced Immune Function Post-Intervention
- Enhanced Immune Memory
- Enhanced Immune Modulation
- Enhanced Immune Regulation
- Enhanced Immune Response
- Enhanced Immune Response Regulation
- Enhanced Immune Response to Gram-Positive Bacteria
- Enhanced Immune Signaling Molecule Production
- Enhanced Immune Status
- Enhanced Immune System Function
- Enhanced Immunity
- Enhanced Immunogenicity
- Enhanced Immunomodulatory Function
- Enhanced Immunoregulatory Function
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Innate Immune Response
- Enhanced Interferon Gamma Production
- Enhanced Interleukin-10 Production
- Enhanced Leukocyte Recruitment
- Enhanced Lymphocyte Proliferation
- Enhanced Phagocytic Activity
- Enhanced Phenoloxidase Activity
- Enhanced Phenotypic Maturation of Dendritic Cells
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Protection Against Streptococcal Infection
- Enhanced Radical Scavenging Ability
- Enhanced Regulatory Immune System Development
- Enhanced Regulatory T Cell Development
- Enhanced Regulatory T Cell Function
- Enhanced Serum ACH50 Activity
- Enhanced Serum Metabolite Levels Against Inflammation
- Enhanced Serum Peroxidase Activity
- Enhanced Specific IgG Response
- Enhanced Spleen Cell Proliferative Response
- Enhanced T Cell Activation
- Enhanced T- and B-Lymphocyte Proliferation
- Enhanced T-Cell Response
- Enhanced Treg Cell Differentiation
- Enhanced Type 1 Immune Response
- Good Tolerability
- Identification of FDA Approved Drug Target Regulators
- Improved ACR20 Response
- Improved Activities of Daily Living
- Improved Adherence Ability
- Improved Adhesion Capacity
- Improved Agility Performance
- Improved Alternative Complement Pathway Activity
- Improved Antigen Presentation
- Improved Antigen-Presenting Ability of Dendritic Cells
- Improved Antioxidant Capacity
- Improved Antioxidant Defense
- Improved Antioxidant Function
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Antioxidative Enzyme Activities
- Improved Antioxidative Response
- Improved B Cell Recovery
- Improved Bone Health
- Improved Bone Preservation
- Improved Cellular Immune Response
- Improved Cellular Immunity
- Improved Clinical Disease Activity
- Improved Clinical Success
- Improved Connective Tissue Attachment Levels
- Improved Cyclophosphamide-Induced Immunosuppression
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Daily Activity Participation
- Improved Dendritic Cell Activation
- Improved Disease Activity Index Score
- Improved Diversification of B-Cell Populations
- Improved Dry Eye Symptoms
- Improved Ease of Use
- Improved Efficacy Rate
- Improved Fatigue
- Improved Fatigue Symptoms
- Improved Fine Motor Skills
- Improved Function Score
- Improved Functional Recovery
- Improved General Health Perception
- Improved General Tolerance
- Improved Global Evaluation of Patient Score
- Improved Global Evaluation of Patient Scores
- Improved Global Quality of Life
- Improved Global Symptom
- Improved Global Symptom Assessment
- Improved Granulocyte Oxidative Burst
- Improved Health Perception
- Improved Health Status
- Improved Health-related Quality of Life
- Improved Histopathological Protection
- Improved Human Health
- Improved Humoral Immune Parameters
- Improved Humoral Immunity
- Improved IL-10/TNF-α Ratio
- Improved IgG Response to Vaccination
- Improved Immune Activation
- Improved Immune Modulation
- Improved Immune Organ Development
- Improved Immune Parameters
- Improved Immune Regulation
- Improved Immune Response in Individuals with Poor Pretreatment
- Improved Immune Response to Influenza A
- Improved Immune Surveillance
- Improved Immune System Dialog via EPS
- Improved Immune System Function via JAK-STAT Pathway Activation
- Improved Immune System Maturation
- Improved Immune System Modulation
- Improved Immune Tolerance
- Improved Immune-Related Symptoms
- Improved Immunity Biomarkers
- Improved Immunity Pathways
- Improved Immunity Status
- Improved Immunoglobulin Levels
- Improved Immunoinflammatory Markers
- Improved Immunological Biomarkers
- Improved Immunological Indices
- Improved Immunomodulation
- Improved Inflammation Homeostasis
- Improved Inflammation Levels
- Improved Inflammatory Biomarkers
- Improved Inflammatory Marker Profile
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Inflammatory Status
- Improved Innate Humoral Immunity
- Improved Interleukin-10 Levels
- Improved Isokinetic Strength
- Improved Joint Function
- Improved Knee Extensor Strength
- Improved Knee Joint Extensor Strength
- Improved Lower-Body Muscular Strength
- Improved Mechanical Properties
- Improved Monocyte Activation
- Improved Natural Killer Cell Function
- Improved Neutrophil Function
- Improved Orthopedic Function
- Improved Overall Patient Outcomes
- Improved Overall Symptom Relief
- Improved Overall Symptom Score
- Improved Overall Symptoms
- Improved Oxidative Status
- Improved Oxidative Stress Biomarker
- Improved Oxidative Stress Levels
- Improved Oxidative Stress Marker
- Improved Oxidative Stress Tolerance
- Improved Pain Intensity
- Improved Pain Management
- Improved Pain Scale
- Improved Pain Score
- Improved Pain Threshold
- Improved Patient Global Assessment
- Improved Patient Global Impression of Change (PGI-C) Scores
- Improved Perceived Health
- Improved Peripheral Blood Lymphocyte Proliferation
- Improved Peripheral Inflammation
- Improved Phagocytic Activity of Granulocytes
- Improved Phagocytosis
- Improved Physical Domain Score
- Improved Physical Function
- Improved Physical Health-Related Quality of Life
- Improved Physical Mobility
- Improved Physical Quality of Life
- Improved Physical Role Limitation
- Improved Physical Well-being
- Improved Physician Global Assessment
- Improved Pre-Mortality General Health Score
- Improved Presenteeism
- Improved Pressure Pain Threshold
- Improved Protein Kinase C Activity
- Improved Quadriceps Endurance
- Improved Quadriceps Strength
- Improved Quality of Life
- Improved Radiographic Success
- Improved Regulatory T Cell Function
- Improved Remission
- Improved Remission Rate
- Improved Responder Rate
- Improved Response Rate
- Improved Response to Treatment
- Improved Secondary Symptoms
- Improved Self-assessed Disability
- Improved Serum Antioxidant Capacity
- Improved Serum Biochemical HA Levels
- Improved Serum Hyaluronan Levels
- Improved Serum SOD Activity
- Improved Specific Elements Within Assessed Measures
- Improved Spleen T-Cell Function
- Improved Stiffness
- Improved Superoxide Dismutase Level
- Improved Symptom Control
- Improved Symptom Control in Degenerative Joint Disease
- Improved Symptom Relief
- Improved Symptom Score
- Improved Symptoms of Chronic Condition
- Improved Systemic Immune Response
- Improved T Helper Cell Count
- Improved T Lymphocyte Subset Balance
- Improved T-Cell Cytokine Production
- Improved T-cell Proliferative Response
- Improved Th1 Immunity
- Improved Th1/Th2 Balance
- Improved Therapeutic Potential
- Improved Tissue Pathology
- Improved Tolerance
- Improved Treatment Efficacy
- Improved Treg/Th-17 Balance
- Improved Vaccine Efficacy
- Improved Vaccine Seroconversion
- Improved Walking Ability
- Improved n-6 to n-3 PUFA Ratio
- Increased Acceptability of Use
- Increased Activation of Regulatory T Cells
- Increased Analgesic Capacity
- Increased Anti-Inflammatory Bacteria Abundance
- Increased Anti-Inflammatory Cytokine IL-10
- Increased Anti-Inflammatory Cytokine IL-6 Production
- Increased Anti-Inflammatory Cytokine Levels
- Increased Anti-Inflammatory Immune Cell Populations
- Increased Anti-Inflammatory Levels
- Increased Anti-Osteoclastogenic Cytokine Production
- Increased Anti-inflammatory Cytokines
- Increased Anti-inflammatory Phenotype in Dendritic Cells
- Increased Anti-inflammatory to Pro-inflammatory Cytokine Ratio
- Increased Antibody Production
- Increased Antigen-Presenting Cell Activation
- Increased Antigen-Specific IgG1 Levels
- Increased Antioxidant Activity
- Increased Antioxidant Enzyme Levels
- Increased Antioxidant Potential
- Increased Apoptosis in T Cells
- Increased Apoptosis of OVA-specific TCR Tg T Cells
- Increased B Cell Activation
- Increased B Cell Count
- Increased B Cell Populations
- Increased Bone Marrow Myelopoiesis
- Increased C-Reactive Protein Level
- Increased C-Reactive Protein Levels
- Increased CCL-20 Levels
- Increased CD163+ Macrophage Density
- Increased CD4+ and CD8+ T Cell Proportion
- Increased CD4+CD25+ T Cell Numbers
- Increased CD4-CD8 Ratio
- Increased CD4-Positive T-Lymphocytes
- Increased CD68+ Macrophage Density
- Increased CD8 Percentage
- Increased Circulating 25-Hydroxyvitamin D Levels
- Increased Circulating Immune Cell Count
- Increased Complement C3 Level
- Increased Complement Component Levels
- Increased Complement Pathway Activity
- Increased Cytokine Production
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Response
- Increased Cytokine Secretion
- Increased Dendritic Cell Activation
- Increased Expression of Activation Markers on NK Cells
- Increased Expression of CD206
- Increased Expression of Heat Shock Protein 25
- Increased Ferritin Level
- Increased Follicular Helper T Cell Activity
- Increased Foxp3 Protein Levels
- Increased Foxp3+ to IL-10 Ratio
- Increased Functional Genes
- Increased GSH/GSSG Ratio
- Increased Generation of T Regulatory Cells
- Increased Glutathione Peroxidase Level
- Increased Helper T Cell Activation
- Increased Hemocyte Density
- Increased Hyaluronic Acid Molecular Weight
- Increased Hyaluronic Acid Production
- Increased Hydrogen Peroxide Production
- Increased Hypothalamic Expression of Pro-inflammatory Markers
- Increased IFN-gamma Secretion from Naïve T Cells
- Increased IFN-γ Levels
- Increased IFN-γ to IL-4 Ratio
- Increased IL-10 Concentration
- Increased IL-10 Levels
- Increased IL-12 Levels
- Increased IL-12 Production
- Increased IL-12 Production in Splenocytes
- Increased IL-17 Levels
- Increased IL-2 Secretion
- Increased IL-6 Levels in Early Phase
- Increased IgA Production
- Increased Immune Activation without Cytotoxicity
- Increased Immune Cell Presence
- Increased Immune Factor Levels
- Increased Immune Marker Activation
- Increased Immune Marker Levels
- Increased Immune Response
- Increased Immune System Activation
- Increased Immunoglobulin A Levels
- Increased Immunoglobulin G Levels
- Increased Immunoglobulin G1 Levels
- Increased Immunoglobulin G2 Levels
- Increased Immunosuppressive Cytokine Production
- Increased Inflammatory Cell Counts
- Increased Inflammatory Cytokines
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Interferon-Gamma Levels
- Increased Interleukin 12 Secretion from Dendritic Cells
- Increased Interleukin 8 Levels
- Increased Interleukin-1 Beta Production
- Increased Interleukin-1 Receptor Antagonist Production
- Increased Interleukin-10 Levels
- Increased Interleukin-10 Production
- Increased Interleukin-12 Production
- Increased Interleukin-12p40 Production
- Increased Interleukin-2 Production
- Increased Interleukin-6 Production in Macrophages
- Increased Lymphocyte Proliferation
- Increased Lymphoid Cell Proliferation in Germ-Free Animals
- Increased Malondialdehyde Levels
- Increased Memory T Cell Frequency
- Increased Myeloperoxidase Activity
- Increased Natural Killer Cell Frequency
- Increased Natural Killer T Cells
- Increased Nerve Growth Factor Level
- Increased Nrf2 Protein Content
- Increased Osteoprotegerin Immunostaining
- Increased Oxidative Stress
- Increased Pain
- Increased Pain-Free Days
- Increased Perceived Pain
- Increased Peripheral Blood B Cell Frequency
- Increased Peroxidase Levels
- Increased Plasma Anti-inflammatory Cytokine Levels
- Increased Plasma Immunoglobulin Levels
- Increased Pro-inflammatory Cytokine IL-6
- Increased Pro-inflammatory Cytokine Production
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Production of Anti-inflammatory Cytokine IL-10
- Increased Production of Bioactive Metabolites
- Increased Proportion of Activated T Lymphocytes
- Increased Proportion of Responders
- Increased Proportion of T Lymphocytes
- Increased Reactive Oxygen Species Production
- Increased Reactive Oxygen Species Response
- Increased Regulatory T Cell Count
- Increased Regulatory T Cell Expansion
- Increased Regulatory T Cell Frequency
- Increased Regulatory T Cell Induction
- Increased Regulatory T Cell Populations
- Increased Regulatory T Cell Response
- Increased Regulatory T-Cells
- Increased Serum Alternative Complement Activity
- Increased Serum Antioxidant Enzyme Levels
- Increased Serum Ferritin Level
- Increased Serum IL-10 Levels
- Increased Serum IgG2 Levels
- Increased Serum IgM Levels at 30 Days
- Increased Serum Immunoglobulin A (IgA) Levels
- Increased Serum Immunoglobulin Levels
- Increased Serum Immunoglobulins
- Increased Serum Lysozyme Levels
- Increased Serum Metabolites to Combat Inflammation
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Specific Antibody Production
- Increased Specific IgG Levels
- Increased Splenic Lymphocyte Proliferation
- Increased Superoxide Dismutase Activity
- Increased Systemic Antibody Production
- Increased T Cell Activation
- Increased T-helper Type 1 Cytokine Concentrations
- Increased TNF-alpha Levels in Macrophages
- Increased TNF-α Production
- Increased Th1-Associated Cytokine Release
- Increased Th17 Polarization
- Increased Thiol Level
- Increased Tolerability
- Increased Tolerance to Inflammatory Stimuli
- Increased Tolerogenic Dendritic Cells
- Increased Total Radical-Trapping Antioxidant Parameter Levels
- Increased Transforming Growth Factor-β Levels
- Increased Treatment Effectiveness
- Increased Treg Cell Fraction
- Increased Treg Frequency at 7 Days
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased Tumor Necrosis Factor-Alpha Production by Dendritic Cells
- Increased Type I Interferon Production
- Increased n-3 Polyunsaturated Fatty Acid Levels
- Induced Immunomodulatory Effects
- Induced Th1 Cytokines
- Induction of Th1 Immune Response
- Inflammatory Disease Protection
- Influenced Systemic Immune Response
- Inhibited Autoimmune Activation
- Inhibited IκBα Degradation
- Long-Lasting Immunomodulatory Effects After Weaning
- Maintained Immune Homeostasis
- Maintained Physical Activity Level
- Maintained Physical Performance
- Matured Antigen-Presenting Cells
- Modulated Cytokine Levels
- Modulated Cytokine Production
- Modulated Dendritic Cell Function
- Modulated Eicosanoid Levels
- Modulated Host Immune Response
- Modulated Host Response
- Modulated Humoral Inflammation
- Modulated Immune Function in Offspring
- Modulated Immune Markers
- Modulated Immune Response
- Modulated Immune System
- Modulated Immune Tolerance
- Modulated Immunoinflammatory Parameters
- Modulated Immunologic Response
- Modulated Immunological Profile
- Modulated Inflammation and Coagulation Interaction
- Modulated Inflammatory Cytokine Levels
- Modulated Inflammatory Response
- Modulated Innate Immune Response
- Modulated Lymphocyte Populations
- Modulated Nociceptive Signaling
- Modulated Peripheral Immune Response
- Modulated Systemic Immune Response
- Modulated Systemic Th1/Th2 Balance
- Modulated T Cell Response
- No Adverse Safety Findings
- No Change in C-Reactive Protein
- No Change in Inflammation Markers
- No Change in Negative Mood States
- No Change in Proinflammatory Cytokine Secretion
- No Change in Vaccine Responses
- No Change in Weight Gain
- No Clear Clinical Benefit
- No Meaningful Change in IL-10
- No Meaningful Change in IL-6
- No Meaningful Change in IL-8
- No Serious Treatment-Related Adverse Events
- No Significant Change in Hip Joint Bone Mineral Density
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- No Significant Effect on C-Reactive Protein Levels
- No Significant Impact on Bacterial Community Composition or Diversity
- Normalized Serum IL-10 Levels
- Normalized Serum IL-1β Levels
- Prevention and Treatment of Inflammatory Diseases
- Prevention of Aberrant Inflammatory Response
- Prevention of Autoimmune Disorders
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced Abundance of Pro-inflammatory Bacteria
- Reduced Activated B Cells
- Reduced Age-Related Inflammation
- Reduced Aggravation of Chronic Inflammation
- Reduced Allograft Rejection
- Reduced Analgesic Usage
- Reduced Analgesic Use
- Reduced Anti-citrullinated Protein Antibodies Levels
- Reduced Arthritis Incidence
- Reduced Arthritis Score
- Reduced Arthritis Severity
- Reduced Arthritis Symptoms
- Reduced Average Pain
- Reduced B Cell Count in Draining Lymph Nodes
- Reduced B Lymphocyte Proliferation
- Reduced Bodily Pain
- Reduced Bone Erosion
- Reduced C-Reactive Protein Level
- Reduced C-Reactive Protein Levels
- Reduced CD25+ Cells
- Reduced CD28 Expression Loss in CD8+ T Cells
- Reduced CD8 Cell Percentage
- Reduced CD8+ Lymphocytes Count
- Reduced COX-2 Levels
- Reduced CTLA-4 Expression on CD4 T Cells
- Reduced CTLA-4 Induction on CD4 T Cells
- Reduced Cervical Lymphadenopathy Symptoms
- Reduced Chemokine Levels
- Reduced Chemokine Production
- Reduced Clinical Symptoms of Arthritis
- Reduced Concomitant Medication Usage
- Reduced Corticosteroid Usage
- Reduced Creatine Kinase Activity
- Reduced Cyclooxygenase-2 Levels
- Reduced Cytokine Response
- Reduced Cytokine Secretion in Dendritic Cells
- Reduced Cytotoxic Effects
- Reduced Dendritic Cell Function
- Reduced Disability
- Reduced Discomfort
- Reduced Disease Activity
- Reduced Disease Activity Index (DAI) Levels
- Reduced Disease Activity Index Scores
- Reduced Disease Activity Score
- Reduced Disease Progression
- Reduced Disease Severity
- Reduced Disease Symptoms
- Reduced Exercise-Induced Biochemical Markers
- Reduced Expression of ADAM17
- Reduced Expression of Inflammation-Related Genes
- Reduced Expression of Proinflammatory Mediators
- Reduced Fat-Free Mass
- Reduced Fatigue Severity
- Reduced Free Radical Levels
- Reduced Germinal Center B Cells in Draining Lymph Nodes
- Reduced High-Sensitivity C-Reactive Protein
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Histological Damage Scores
- Reduced Histopathological Damage
- Reduced Hyaluronidase Activity
- Reduced Hydrogen Sulfide Level
- Reduced IFN-γ Levels
- Reduced IFN-γ in Serum
- Reduced IL-12p70 Release
- Reduced IL-17 Production in Splenocytes
- Reduced IL-1β Levels
- Reduced IL-6 Concentration
- Reduced IL-6 Levels
- Reduced IL-6 Production
- Reduced IL-6 Secretion
- Reduced IL-8 Secretion
- Reduced IkappaB Alpha Degradation
- Reduced Immune Activation
- Reduced Immune-Mediated Pathologies
- Reduced Immunoinflammatory Markers
- Reduced Immunological Pathway Activity in Antigen Presentation
- Reduced Infection Frequency
- Reduced Inflammation
- Reduced Inflammation Levels
- Reduced Inflammation Markers
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammation via Gut Microbiota
- Reduced Inflammatory Activities
- Reduced Inflammatory Biomarker Level
- Reduced Inflammatory Cell Activity
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Diseases
- Reduced Inflammatory Effects
- Reduced Inflammatory Factor Production
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Infiltrate
- Reduced Inflammatory Injury
- Reduced Inflammatory Marker IL-1β
- Reduced Inflammatory Marker Protein Levels
- Reduced Inflammatory Markers
- Reduced Inflammatory Markers in Aqueous Humour
- Reduced Inflammatory Mediators
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Pathways
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Response
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Inflammatory Status
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Tone
- Reduced Intercellular Adhesion Molecule-1
- Reduced Interference Score
- Reduced Interference with Daily Life
- Reduced Interleukin Level
- Reduced Interleukin-1 Level
- Reduced Interleukin-10 Levels
- Reduced Interleukin-15 Levels
- Reduced Interleukin-1β Concentration
- Reduced Interleukin-1β Levels
- Reduced Interleukin-22 Level
- Reduced Interleukin-6 Levels
- Reduced Interleukin-6 Production
- Reduced Interleukin-8 Secretion
- Reduced Joint Damage
- Reduced Joint Inflammation
- Reduced Joint Swelling
- Reduced Joint Tenderness
- Reduced Knee Pain
- Reduced LPS-Induced Cellular Activity
- Reduced LPS-Induced Inflammation
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Interleukin-17
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Levels of Receptor Activator of Nuclear Factor-kappa B Ligand
- Reduced Local Inflammation
- Reduced Low-Grade Inflammation
- Reduced Lymphocytic Genome Damage
- Reduced MAPK Activation
- Reduced MCP-1/CCL2 Levels
- Reduced Microbial Richness
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Mycobacterium bovis BCG Phagocytic Uptake
- Reduced Myeloperoxidase Activity
- Reduced NADPH Oxidase Activity
- Reduced NF-kappaB-DNA Binding
- Reduced Naïve CD45RA+ Th Cell Count
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Neutrophil Infiltration
- Reduced Neutrophil Recruitment
- Reduced Nuclear Factor Kappa B Activation
- Reduced Osteoclast Differentiation Markers
- Reduced Overall Symptoms
- Reduced Oxidative Damage
- Reduced Oxidative Damage in Serum
- Reduced Oxidative Stress
- Reduced Oxidative Stress Marker
- Reduced Oxidative Stress Marker Level
- Reduced Oxidative Stress Markers
- Reduced P1NP Level
- Reduced PMA Index
- Reduced PMN Cell Migration Towards Inflammatory Mediators
- Reduced Pain
- Reduced Pain Assessment Score
- Reduced Pain During Movement
- Reduced Pain Frequency
- Reduced Pain Intensity
- Reduced Pain Levels
- Reduced Pain Scale
- Reduced Pain Score
- Reduced Pain Sensitivity
- Reduced Pain Severity
- Reduced Pain Symptom Score
- Reduced Pain Symptoms
- Reduced Pain-Related Disability
- Reduced Painkiller Consumption
- Reduced Paw Volume
- Reduced Peripheral Inflammation
- Reduced Phospho-p65 Translocation
- Reduced Plasma CRP Levels
- Reduced Plasma IL-10 Levels
- Reduced Plasma IgG Production
- Reduced Plasma Malondialdehyde Levels
- Reduced Plasma Tumor Necrosis Factor-α Levels
- Reduced Postoperative Fatigue
- Reduced Postoperative Pain
- Reduced Pro-Inflammatory Bacteria Levels
- Reduced Pro-Inflammatory Cells
- Reduced Pro-Inflammatory Cytokine Interleukin-15 Levels
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-Inflammatory Mediator Production
- Reduced Pro-inflammatory Biomarker Level
- Reduced Pro-inflammatory Cytokine Interleukin-8 Levels
- Reduced Pro-inflammatory Cytokine Levels
- Reduced Pro-inflammatory Cytokine Production in LPS-stimulated Cells
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Immune Responses
- Reduced Pro-inflammatory Mediator Levels
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokine Secretion
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factor Levels
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Proinflammatory Profile from Cow Milk Formula
- Reduced Proinflammatory Signaling
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Proliferation of CD4(+) T Cells
- Reduced Proportion of Volunteers with At Least One CID
- Reduced Protein Carbonyl Levels
- Reduced Quadriceps Muscle Cross-Sectional Area
- Reduced RANKL/OPG Ratio
- Reduced Relapse Rate
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Rheumatoid Factor Level
- Reduced Risk Factors for Multiple Sclerosis
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Risk of Low Bone Mineral Density
- Reduced Salivary Gamma-Interferon Levels
- Reduced Serious Adverse Events
- Reduced Serum Amyloid A Levels
- Reduced Serum C-reactive Protein Levels
- Reduced Serum Chemokine Levels
- Reduced Serum Collagen Type II C-Telopeptide (sCTX-II)
- Reduced Serum Cytokine Levels
- Reduced Serum IL-16 Levels
- Reduced Serum IL-6 Levels
- Reduced Serum Inflammatory Cytokines
- Reduced Serum Inflammatory Factors
- Reduced Serum LPS Levels
- Reduced Serum Level of CII-specific Antibodies
- Reduced Serum TNF-Alpha Level
- Reduced Serum TNF-α Levels
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Serum Undercarboxylated Osteocalcin Concentration
- Reduced Soluble VCAM-1 Levels
- Reduced Soreness
- Reduced Standard Care Medication Need
- Reduced Steroid Load
- Reduced Steroid Usage
- Reduced Stiffness
- Reduced Surface Skewness
- Reduced Susceptibility to Inflammatory Exposure
- Reduced Swelling
- Reduced Swollen Joint Count
- Reduced Symptom Severity
- Reduced Symptom Severity Scale Score
- Reduced Synovial Infiltration
- Reduced Systemic Inflammatory Response
- Reduced T Cell Responsiveness
- Reduced T-Effector Memory Cell Activity
- Reduced TH17 Response
- Reduced TLR Inflammatory Activation
- Reduced TNF Production
- Reduced TNF-alpha Level
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced TNF-α Secretion
- Reduced TNF-α Signaling
- Reduced TRPV1 Activation
- Reduced Tender Joint Count
- Reduced Th1/Th2 Ratio
- Reduced Th17 Cell Fraction
- Reduced Thymus and Activation-Regulated Chemokine Level
- Reduced Total Analgesic Dosage
- Reduced Total Immune Cells in Draining Lymph Nodes
- Reduced Transforming Growth Factor Beta Levels
- Reduced Tumor Necrosis Factor Alpha
- Reduced Tumor Necrosis Factor Alpha Production
- Reduced Tumor Necrosis Factor-alpha Level
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced Tumor Necrosis Factor-α Levels
- Reduced Worst Pain
- Reduced hsCRP Level
- Regulated Cytokine Levels
- Regulated Immune Cell Proliferation
- Regulated Immune Response
- Regulated Inflammation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Inflammatory Process
- Regulated Inflammatory Responses
- Regulated Interleukin 8 Levels
- Regulated Oxidative Stress
- Regulated Systemic Immune Response Imbalance
- Restored Immune Organ Structure
- Restored Immunological Function in Immunosuppressed Mice
- Restored Regulatory T Cell Population
- Restored SOD Activity Levels
- Restored Th1/Th2 Cytokine Balance
- Restored Treg Cell Population in MLNs
- Safe Drug Administration
- Safety Comparable to Control
- Stabilized Cytokine Levels
- Stabilized Disease Progression
- Stabilized Natural Killer Cell Activity
- Stable Immune System Responses
- Stable Inflammatory Responses
- Stable Proinflammatory Cytokine Levels
- Stable Systemic Inflammatory Response
- Stimulation of Immune Cells
- Suppressed Inflammatory Chemokine Secretion
- Suppressed TNF-α Induced Genes
- Sustained Anti-Inflammatory Gene Transcription
- Th1 Polarized Immune Response Through Activation of moDCs
- Unchanged Biochemical Parameters
- Unchanged Heat Shock Protein Levels
- Unchanged IFN-γ Levels
- Unchanged Inflammatory Marker Levels
- Unchanged Inflammatory Marker Production
- Unchanged Interleukin-6 Levels
- Unchanged Microbiome Alpha-Diversity
- Unchanged Risk of Sepsis
- Unchanged Spleen Weight Index
- Unchanged Symptom Severity
- Upregulated Macrophage Inhibitory Factor
- Well-Tolerated Long-Term Use
- Well-Tolerated Supplementation
- Worsened Autoimmune Manifestations